Palvella Therapeutics Employee Directory
Biotechnology ResearchPennsylvania, United States11-50 Employees
Palvella Therapeutics is a clinical-stage biotechnology company based in Wayne, Pennsylvania, focused on developing therapies for serious, rare genetic skin diseases and vascular malformations for which there are no FDA-approved treatments. The company is building a broad pipeline around its QTORIN platform, concentrating on lifelong skin conditions with limited or no existing therapies. Its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, is in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It is also advancing QTORIN pitavastatin for disseminated superficial actinic porokeratosis. In 2026 Palvella presented clinical results from its QTORIN rapamycin program at the ISSVA World Congress 2026 in Philadelphia and has engaged with industry events, including the Goldman Sachs Global Healthcare Conference. Palvella was recognized as Healthcare & Life Sciences Company of the Year at the PACT Ecosystem Awards in 2026.